Efficacy of a phosphorodiamidate morpholino oligomer antisense compound in the inhibition of corneal transplant rejection in a rat cornea transplant model

Journal of Ocular Pharmacology and Therapeutics

Volumn 28, Issue 2, 2012, Pages 194-201

  Hosseini, Alireza ^a   Lattanzio, Frank A ^a,b   Samudre, Sandeep S ^a,b   Disandro, Giovanni ^a   Sheppard, John D ^a,c   Williams, Patricia B ^a,b  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b EyeRx Research   (United States)

^c Virginia Eye Consultants   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; AVI 5126; DEXAMETHASONE PLUS TOBRAMYCIN; MORPHOLINO OLIGONUCLEOTIDE; SULFACETAMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DENSITY; CONTROLLED STUDY; CORNEA TRANSPLANTATION; DRUG DEGRADATION; DRUG EFFICACY; DRUG SAFETY; DRUG STABILITY; DRUG TOLERABILITY; DRUG TRANSPORT; ENDOTHELIUM CELL; EYE TOXICITY; FEMALE; GENE EXPRESSION; GRAFT REJECTION; GRAFT SURVIVAL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MCDONALDS SHADDUCK SLIT LAMP SCALE; NONHUMAN; ONCOGENE C MYC; POSTOPERATIVE PERIOD; RABBIT; RAT; RATING SCALE;

EID: 84859374023     PISSN: 10807683     EISSN: 15577732     Source Type: Journal    
DOI: 10.1089/jop.2011.0135     Document Type: Article

References (34)

1. Shimmura, S. Component surgery of the cornea. Cornea 28 Suppl):S31-S35, 2004. (Pubitemid 39458541)
2. Price, M.O., Thompson, R.W., Jr., and Price. F.W., Jr. Risk factors for various causes of failure in initial corneal grafts. Arch. Ophthalmol. 121:1087-1092, 2003. (Pubitemid 36962160)
3. Bahar, I., Kaiserman. I., Srinivasan. S., et al. Comparison of three different techniques of corneal transplantation for keratoconus. Am. J. Ophthalmol. 146:905-12 e1, 2008.
4. Lee, H.S., and Kim, M.S. Influential factors on the survival of endothelial cells after penetrating keratoplasty. Eur. J. Oph-thalmol. 19:930-935, 2009.
5. He, Y.G., and Niederkorn, J.Y. Depletion of donor-derived Langerhans cells promotes corneal allograft survival. Cornea 15:82-89, 1996. (Pubitemid 26004914)
6. Walkenbach, R.J., Boney, F., and Ye, G.S. Corneal function after storage in dexsol or optisol. Invest. Ophthalmol. Vis. Sci. 33:2454-2458, 1992.
7. Panda, A., Vanathi, M., Kumar, A., et al. Corneal graft rejection. Surv. Ophthalmol. 52:375-396, 2007. (Pubitemid 46901076)
8. Rinne, J.R., and Stulting, R.D. Current practices in the prevention and treatment of corneal graft rejection. Cornea 11:326-328, 1992.
9. Hill, J.C., Maske, R., and Watson, P.G. The use of a single pulse of intravenous methylprednisolone in the treatment of corneal graft rejection. A preliminary report. Eye 5 (Pt 4):420-424, 1991.
10. Wilhelmus, K.R., Hunter, P.A., and Rice, N.S. Equivalence of topical clobetasone and dexamethasone in experimental cor-neal allograft rejection. Br. J. Ophthalmol. 65:699-701, 1981. (Pubitemid 12228458)
11. Hudde, T., Minassian, D.C., and Larkin, D.F. Randomised controlled trial of corticosteroid regimens in endothelial cor-neal allograft rejection. Br. J. Ophthalmol. 83:1348-1352, 1999.
12. Borel, J.F., Feurer, C., Magnee, C., et al. Effects of the new anti-lymphocytic peptide cyclosporin A in animals. Immunology 32:1017-1025, 1977. (Pubitemid 8120594)
13. Newton, C., Gebhardt, B.M., and Kaufman, H.E. Topically applied cyclosporine in azone prolongs corneal allograft survival. Invest. Ophthalmol. Vis. Sci. 29:208-215, 1988. (Pubitemid 18057568)
14. Zhao, J.C., and Jin, X.Y. Local therapy of corneal allograft rejection with cyclosporine. Am. J. Ophthalmol. 119:189-194, 1995.
15. Hikita, N., Lopez, J.S., Chan, C.C., et al. Use of topical FK506 in a corneal graft rejection model in Lewis rats. Invest. Ophthalmol. Vis. Sci. 38:901-909, 1997. (Pubitemid 27193516)
16. Shi, W., Gao, H., Xie, L., et al. Sustained intraocular rapa-mycin delivery effectively prevents high-risk corneal allo-graft rejection and neovascularization in rabbits. Invest. Ophthalmol. Vis. Sci. 47:3339-3344, 2006. (Pubitemid 351639695)
17. Mackay, I.R., Bignell, J.L., Smith, P.H., et al. Prevention of corneal-graft failure with the immunosuppressive drug azathioprine. Lancet 2:479-482, 1967.
18. Gearhart, J., Pashos, E.E., and Prasad, M.K. Pluripotency redux-advances in stem-cell research. N. Engl. J. Med. 357:1469-1472, 2007.
19. Goers, T.A., Ramachandran, S., Aloush, A., et al. De novo production of K-alpha1 tubulin-specific antibodies: role in chronic lung allograft rejection. J. Immunol. 180:4487-4494, 2008.
20. Kaizu, T., Ikeda, A., Nakao, A., et al. Protection of transplant-induced hepatic ischemia/reperfusion injury with carbon monoxide via MEK/ERK1/2 pathway down-regulation. Am. J. Physiol. Gastrointest. Liver. Physiol. 294: G236-G244, 2008.
21. Rao, G.N., Broeckx, J.L., and Church, R.L. Expression of c-myc protooncogene in primary cultures of human corneal stromal cells. Curr. Eye Res. 8:405-413, 1989. (Pubitemid 19112866)
22. Owen, T.A., Cosenza, S.C., Soprano, D.R., et al. Time of c-fos and c-myc expression in human diploid fibroblasts stimulated to proliferate after prolonged periods in quiescence. J. Biol. Chem. 262:15111-15117, 1987. (Pubitemid 17160178)
23. Dean, M., Levine, R.A., Ran, W., et al. Regulation of c-myc transcription and mRNA abundance by serum growth factors and cell contact. J. Biol. Chem. 261:9161-9166, 1986. (Pubitemid 17218188)
24. Sekhon, H.S., London, C.A., Sekhon, M., et al. c-MYC anti-sense phosphosphorodiamidate morpholino oligomer inhibits lung metastasis in a murine tumor model. Lung Cancer 60:347-354, 2008.
25. Kipshidze, N.N., Iversen, P., Kim, H.S., et al. Advanced c-myc antisense (AVI-4126)-eluting phosphorylcholine-coated stent implantation is associated with complete vascular healing and reduced neointimal formation in the porcine coronary restenosis model. Catheter. Cardiovasc. Interv. 61:518-527, 2004. (Pubitemid 38419142)
26. Devi, G.R., Beer, T.M., Corless, C.L., et al. In vivo bioavail-ability and pharmacokinetics of a c-MYC antisense phos-phorodiamidate morpholino oligomer, AVI-4126, in solid tumors. Clin. Cancer Res. 11:3930-3938, 2005. (Pubitemid 40685615)
27. Arora, V., Knapp, D.C., Reddy, M.T., et al. Bioavailability and efficacy of antisense morpholino oligomers targeted to c-myc and cytochrome P-450 3A2 following oral administration in rats. J. Pharm. Sci. 91:1009-1018, 2002. (Pubitemid 34640926)
28. Szaflik, J., Liberek, I., and Brix, M. Corneal storage methods. Transplant. Proc. 32:1424-1425, 2000.
29. McDonald TaS, J.A. Eye Irritation. In: Marzulli FaM, H.I., ed. Dermatotoxicity and Pharmacology. New York: John Wiley & Sons, Inc.; 1977.
30. Amantana, A., Moulton, H.M., Cate, M.L., et al. Phar-macokinetics, biodistribution, stability and toxicity of a cell-penetrating peptide-morpholino oligomer conjugate. Bioconjug. Chem. 18:1325-1331, 2007. (Pubitemid 47122656)
31. Niederkorn, J.Y. Immune mechanisms of corneal allograft rejection. Curr. Eye Res. 32:1005-1016, 2007. (Pubitemid 351412293)
32. Luengo Gimeno, F., Lang, M., Mehta, J.S., et al. Descemet's stripping automated endothelial keratoplasty: past, present and future. Expert Rev. Ophthalmol. 5:303-311, 2010.
33. Armitage, W.J. Preservation of human cornea. Transfus. Med. Hemother. 38:143-147, 2011.
34. Patel, N.P., Kim, T., Rapuano, C.J., et al. Indications for and outcomes of repeat penetrating keratoplasty, 1989-1995. Ophthalmology 107:719-724, 2000. (Pubitemid 30191339)